Epidemiology-based wastewater monitoring for ecological risks of anti-tuberculosis drugs mixture effects

被引:2
|
作者
Chen, Wei -Yu [1 ]
Chen, Yi-Fang [2 ]
Tsai, Jer-Min [3 ]
Huang, Hsin-Mei [1 ]
Su, Yong -Chao [2 ]
机构
[1] Natl Univ Tainan, Dept Ecol & Environm Resources, Tainan, Taiwan
[2] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan
[3] Kun Shan Univ, Dept Informat & Commun, Tainan, Taiwan
关键词
Anti -tuberculosis drugs; Mixture toxicity; Daphnia magna; Epidemic models; Ecotoxicological risk; PULMONARY TUBERCULOSIS; SEASONALITY; TOXICITY; RIFAMPICIN; ETHAMBUTOL; ANTIBIOTICS; INFLUENZA; HEPATOTOXICITY; NEUROTOXICITY; HEPATOCYTES;
D O I
10.1016/j.scitotenv.2023.164560
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
First-line anti-tuberculosis (TB) drugs are commonly used to treat TB worldwide, leading to more contaminated wastewater being widely discharged into aquatic environments. However, studies of mixture interactions of anti-TB drugs and their residues in aquatic environments are scarce. This study aimed to determine the toxic interactions of antiTB drugs-isoniazid (INH), rifampicin (RMP), and ethambutol (EMB)-in binary and ternary mixtures on Daphnia magna and used the epidemiology of TB history to construct epidemiology-based wastewater monitoring for assessing the environmental release of residues and related ecological risks. The acute immobilization of median effect concentrations (EC50) was 25.6 mg L-1 for INH, 80.9 mg L-1 for RMP, and 188.8 mg L-1 for EMB, as toxic units (TUs) for assessing mixture toxicity. The ternary mixture exhibited the lowest TUs at 50 % effects with 1.12, followed by 1.28 for RMP + EMB, 1.54 for INH + RMP, and 1.93 for INH + EMB, indicating antagonistic interactions. Nevertheless, the combination index (CBI) was used to examine the mixture toxicity in response to immobilization, revealing that the ternary mixture of CBI ranged from 1.01 to 1.08, tending to have a nearly additive effect when suffering >50 % effect (at high concentration levels). The forecasted environmentally relevant concentrations of anti-TB drugs have been on downward trends with ng L-1 level from 2020 to 2030 in Kaohsiung, Taiwan. Although ecotoxicological risks from the wastewater treatment plant and receiving water in the field were slightly greater than the prediction from epidemiology-based wastewater monitoring, there were no risk concerns. Here, we achieved the establishment of evidence that anti-TB drug mixtures' interaction and epidemiological-based monitoring support a systematic approach, resolving the absence of the mixture toxicity information for anti-TB mixture risk assessment in aquatic environments.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis
    Wu, Chunli
    Yi, Hengzhong
    Hu, Yanmei
    Luo, Danlin
    Tang, Zhigang
    Wen, Xinmin
    Zhang, Yong
    Tang, Mi
    Zhang, Lizhi
    Wu, Shu
    Chen, Mengshi
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [22] Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
    Verbeeck, Roger K.
    Guenther, Gunar
    Kibuule, Dan
    Hunter, Christian
    Rennie, Tim W.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (08) : 905 - 916
  • [23] Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
    Roger K. Verbeeck
    Gunar Günther
    Dan Kibuule
    Christian Hunter
    Tim W. Rennie
    European Journal of Clinical Pharmacology, 2016, 72 : 905 - 916
  • [24] An efficient CRISPR interference-based prediction method for synergistic/additive effects of novel combinations of anti-tuberculosis drugs
    Samukawa, Noriaki
    Yamaguchi, Takehiro
    Ozeki, Yuriko
    Matsumoto, Sohkichi
    Igarashi, Masayuki
    Kinoshita, Naoko
    Hatano, Masaki
    Tokudome, Kentaro
    Matsunaga, Shinji
    Tomita, Shuhei
    MICROBIOLOGY-SGM, 2022, 168 (12):
  • [25] A STUDY OF PERVASIVENESS OF HEPATOTOXICITY AND OTHER SIDE EFFECTS OF ANTI-TUBERCULOSIS DRUGS ON PULMONARY KOCH PATIENTS
    Mounika, K. L.
    Swapna, Katla
    Jyothirmai, J.
    Firdous, Nisa
    Ramidi, Prasanna
    Sucharitha, Karra
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (05): : 3954 - 3959
  • [26] The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages
    Chesdachai, Supavit
    Zughaier, Susu M.
    Hao, Li
    Kempker, Russell R.
    Blumberg, Henry M.
    Ziegler, Thomas R.
    Tangpricha, Vin
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2016, 6 : 23 - 29
  • [28] Clinical Trial: Magnetoplasmonic ELISA for Urine-based Active Tuberculosis Detection and Anti-Tuberculosis Therapy Monitoring
    Kim, Jeonghyo
    Tran, Van Tan
    Oh, Sangjin
    Jang, Minji
    Lee, Dong Kun
    Hong, Jong Chul
    Park, Tae Jung
    Kim, Hwa-Jung
    Lee, Jaebeom
    ACS CENTRAL SCIENCE, 2021, 7 (11) : 1898 - 1907
  • [29] Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products
    Catalani, E
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1999, 3 (11) : S289 - S291
  • [30] Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children
    Martial, Lisa C.
    Kerkhoff, Jordy
    Martinez, Nilza
    Rodriguez, Mabel
    Coronel, Rosarito
    Molinas, Gladys
    Roman, Myriam
    Gomez, Roscio
    Aguirre, Sarita
    Jongedijk, Erwin
    Huisman, Justine
    Touw, Daan J.
    Perez, Domingo
    Chaparro, Gilberto
    Gonzalez, Felipe
    Aarnoutse, Rob E.
    Alffenaar, Jan-Willem
    Magis-Escurra, Cecile
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (01) : 109 - 113